Leeds Teaching Hospital’s Ophthalmology Team is celebrating a significant achievement in the international CLARITY clinical trial, a pioneering study investigating a novel JAK-inhibitor biologic treatment for patients with ocular inflammation and uveitis. Led by Principal Investigator Dr Kanchan Bhan and Senior Research Nurse Clare Howcroft, the team has worked tirelessly over the past year to deliver outstanding results for our patients and our Trust.
The Leeds team has received a special commendation from the study sponsor, Priovant Pharmaceuticals, recognising us as one of the top ten highest-recruiting sites internationally and the second-highest recruiter in the UK, far surpassing our original target. This achievement has allowed patients across Leeds and the wider Yorkshire region access to an innovative treatment that would otherwise not have been available to them.
The commendation also highlights Leeds as one of the fastest sites worldwide to screen and confirm eligibility for two patients, a testament to the dedication, efficiency and teamwork displayed in the ophthalmology department.
From having no uveitis research just a few years ago to earning international recognition today, this milestone marks a remarkable step forward for the department and patients in our region.